A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Part of paid clinical trials in Mineola, New York.
- Sponsor
- Eikon Therapeutics
- Study ID
- NCT07365319
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
- Non Small Cell Lung Cancer (Squamous or Non Squamous)
- Stage 4 NSCLC
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- EIK1001 — DRUGEIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist
- Pembrolizumab (KEYTRUDA®) — DRUGPD-1 inhibitor
- Placebo — DRUGPlacebo control
- Paclitaxel + Carboplatin — DRUGSOC Chemotherapy for squamous NSCLC
- Nab-paclitaxel + Carboplatin — DRUGSOC Chemotherapy for squamous NSCLC
- Pemetrexed + Cisplatin /Carboplatin — DRUGSOC Chemotherapy for non-squamous NSCLC
Study Details
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Key Dates
- Start date
- May 18, 2026
- Status verified
- May 2026
- Primary completion
- Dec 31, 2035
- Completion
- Dec 31, 2040
Study Design
- Enrollment
- 750 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Arm 1 (Placebo in Combination with SOC)Participants in this arm will receive EIK1001 Placebo + Standard of Care (SOC).
- Experimental: Arm 2 (EIK1001 in Combination with SOC)Participants in this arm will receive EIK1001 (Selected Dose 1) + Standard of Care (SOC).
- Experimental: Arm 3 (EIK1001 in Combination with SOC)Participants in this arm will receive EIK1001 (Selected Dose 2) + Standard of Care (SOC).
Primary Outcome Measure
Progression-free survival (PFS) [ Time Frame: Through study completion, up to 6 years ]
Central Contacts
- Elelta Shiferraw314-209-3659
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NYU Langone Hospital Long Island | Mineola | New York | 11501 | - |
| NYU Langone Hospital Manhattan | New York | New York | 10016 | - |
| White Plains Hospital | White Plains | New York | 10601 | - |
Find similar trials in Mineola, NY
Related Studies
- Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the ThoraxPHASE2 · Recruiting · University of Rochester · Rochester, New York